查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1552951

癌胚抗原市場規模、佔有率、趨勢分析報告：按類型、性別、產品、測試、最終用途、地區和細分市場預測，2024-2030 年

Carcinoembryonic Antigen Market Size, Share & Trends Analysis Report By Type (Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer), By Gender, By Product, By Test, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

癌胚抗原市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球癌胚抗原市場規模將達到29.5億美元，2024年至2030年複合年成長率為5.5%。

可與其他生物標記結合使用的新型生物標記開發的持續技術進步預計將在預測期內提高利用率。此外，癌症盛行率的增加預計將增加對有效診斷工具的需求。根據世界衛生組織估計，2012年全球癌症患者人數約1,410萬，其中女性670萬，男性740萬。對微創診斷方法的需求不斷成長預計也將在決定市場成長方面發揮重要作用。微創診斷程序的主要優點包括由於切口較小而提高患者滿意度。此外，這些手術由於住院時間相對較短且術後併發症較少，因此在經濟上是可行的。

癌胚抗原市場報告亮點：

  • 大腸直腸癌是軟骨胚胎抗原市場收益最高的應用領域之一，預計2023年將達到1.9332億美元。大腸直腸癌盛行率的不斷增加以及各個階段癌胚抗原檢測的使用是佔很大比例的重要因素之一。例如，2012年，美國大腸直腸癌新患者估計超過93,000例，僅結直腸癌死亡人數估計就超過49,700例。
  • 基於癌胚抗原的乳癌診斷被認為是市場上最有利可圖的應用領域。該市場將受到50歲以上女性人口增加、荷爾蒙補充療法（HRT）和整容手術需求增加等因素的推動。此外，意識層級的提高和政府有利舉措的存在預計將提高預測期內的治療率。
  • 由於發病率高、報銷框架良好、消費者意識層級高以及醫療保健支出水平相對較高，北美將在 2023 年成為最大的區域市場。
  • 預計亞太地區將在預測期內出現最有利的成長。開拓的機會的存在、醫療基礎設施的不斷改善、經濟發展以及意識層級的提高是促成這一快速成長的因素。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章癌胚抗原市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 癌胚抗原市場分析工具
    • 波特的分析
    • PESTEL分析

第4章癌胚抗原市場：按類型估計和趨勢分析

  • 細分儀表板
  • 癌胚抗原市場：2023年和2030年按類型分類的變化分析
  • 大腸直腸癌
  • 胰臟癌
  • 卵巢癌
  • 乳癌
  • 甲狀腺癌
  • 其他

第5章癌胚抗原市場：性別估計與趨勢分析

  • 細分儀表板
  • 癌胚抗原市場：性別差異分析，2023 年和 2030 年
  • 男性
  • 女士

第6章癌胚抗原市場：依產品估計與趨勢分析

  • 細分儀表板
  • 癌胚抗原市場：2023 年和 2030 年按產品分類的變化分析
  • CD66a
  • CD66b
  • CD66c
  • CD66d
  • CD66f

第7章癌胚抗原市場：測試估計和趨勢分析

  • 細分儀表板
  • 癌胚抗原市場：2023 年和 2030 年測試變化分析
  • 分子檢測
  • 血清檢測

第 8 章癌胚抗原市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 癌胚抗原市場：2023 年和 2030 年最終用途的變化分析
  • 醫院
  • 研究所
  • 其他

第9章癌胚抗原市場：區域估計和趨勢分析

  • 2023 年及 2030 年癌胚抗原市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Quest Diagnostics Incorporated
    • F. Hoffmann-La Roche Ltd
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • Abbott
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Omega Diagnostics Ltd
    • Boster Biological Technology
    • Lee BioSolutions
簡介目錄
Product Code: 978-1-68038-425-3

Carcinoembryonic Antigen Market Growth & Trends:

The global carcinoembryonic antigen market size is expected to reach USD 2.95 billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Constant technological advancements pertaining to the development of novel biomarkers which can be used in combination with other biomarkers is expected to boost usage rates over the forecast period. Furthermore, the increasing prevalence of cancer is expected to heighten the demand for effective diagnostic tools. According to the WHO estimates in 2012, global cancer incidences were nearly 14.1 million, which include 6.7 million female patients and 7.4 million male patients. Increasing demand for minimally invasive diagnostics procedures is also expected to play a vital role in determining market growth. Key advantages associated with minimally invasive diagnostics procedures include elevated patient satisfaction levels as they entail minor incision wounds. In addition, these procedures involve relatively lesser hospital stays and therefore, are economically viable and involve fewer post procedure complications.

Carcinoembryonic Antigen Market Report Highlights:

  • Colorectal cancer was one of the largest revenue generating application segment of the carcinoembryonic antigen market and was estimated at USD 193.32 million in 2023. Increasing prevalence of colorectal cancer and usage of carcinoembryonic antigen tests at various stages is one of the critical factors accounting for its large share. For instance, in 2012, new cases of colorectal cancer were estimated to be over 93,000 and death due to colorectal cancer is expected to be over 49,700 in the U.S alone.
  • Carcinoembryonic antigen based breast cancer diagnosis is identified as the most lucrative application segment of the market. The market is driven by factors such as growing number of female population above 50 years, growing demand for Hormone Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient awareness levels and the presence of favorable government initiatives are expected to improve treatment rates over the forecast period.
  • North America was the largest regional market in 2023 owing to, the presence of high incidence rates, presence of favorable reimbursement framework, and high consumer awareness levels coupled with relatively higher healthcare expenditure levels.
  • Asia Pacific is anticipated to witness the most lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and improving patient awareness levels are some factors accounting for this rapid growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Carcinoembryonic Antigen Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Carcinoembryonic Antigen Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Carcinoembryonic Antigen Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Carcinoembryonic Antigen Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Colorectal Cancer
    • 4.3.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Pancreatic Cancer
    • 4.4.1. Pancreatic Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Ovarian Cancer
    • 4.5.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Thyroid Cancer
    • 4.7.1. Thyroid Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carcinoembryonic Antigen Market: Gender Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Carcinoembryonic Antigen Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Male
    • 5.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Female
    • 5.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carcinoembryonic Antigen Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Carcinoembryonic Antigen Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. CD66a
    • 6.3.1. CD66a Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CD66b
    • 6.4.1. CD66b Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CD66c
    • 6.5.1. CD66c Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CD66d
    • 6.6.1. CD66d Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. CD66f
    • 6.7.1. CD66f Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carcinoembryonic Antigen Market: Test Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Carcinoembryonic Antigen Market: Test Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Molecular Tests
    • 7.3.1. Molecular Tests Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Serology Tests
    • 7.4.1. Serology Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Carcinoembryonic Antigen Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Carcinoembryonic Antigen Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 8.3. Hospitals
    • 8.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Laboratories
    • 8.4.1. Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Others
    • 8.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Carcinoembryonic Antigen Market: Regional Estimates & Trend Analysis

  • 9.1. Carcinoembryonic Antigen Market Share, By Region, 2023 & 2030 (USD Million)
  • 9.2. North America
    • 9.2.1. North America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. China Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Japan Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Australia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Saudi Arabia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. Quest Diagnostics Incorporated
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. F. Hoffmann-La Roche Ltd
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Creative Diagnostics
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Aviva Systems Biology Corporation
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. Abbott
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Laboratory Corporation of America Holdings
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. Merck KGaA
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Omega Diagnostics Ltd
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives
    • 10.4.9. Boster Biological Technology
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments/ Strategic Initiatives
    • 10.4.10. Lee BioSolutions
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments/ Strategic Initiatives